Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal implant for intravitreal administration. It provides sustained anti‑inflammatory therapy for diabetic macular edema in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics and specialty eye‑care centres worldwide. Our global distribution network ensures product integrity and regulatory compliance across EU, North America, Asia‑Pacific and Middle‑East markets. We provide technical support, documentation and reliable logistics for seamless integration into clinical practice.

Iluvien, a fluocinolone acetonide intravitreal implant, is used to manage retinal vascular disease characterized by fluid accumulation.

Diabetic macular edema: reduces retinal swelling and improves visual acuity.

Iluvien may cause ocular adverse reactions that vary in frequency and severity.

Common Side Effects: - Increased intraocular pressure: may require monitoring or treatment. - Cataract progression: especially posterior subcapsular cataract. - Ocular discomfort: transient pain or irritation after implantation. - Reduced visual acuity: temporary blurring during the early post‑implant period.

Serious or Rare Side Effects: - Endophthalmitis: severe intraocular infection requiring urgent therapy. - Retinal detachment: separation of retinal layers that can threaten vision. - Persistent elevated intraocular pressure needing surgical intervention.

When using Iluvien, clinicians should observe several safety considerations to minimize risks. - Patient selection: limit use to adults with chronic diabetic macular edema insufficiently controlled by other therapies. - Intraocular pressure monitoring: check IOP regularly after implantation and manage elevations promptly. - Cataract surveillance: assess lens status periodically, especially in phakic eyes. - Ocular infection risk: avoid implantation in eyes with active infection or inflammation. - Surgical expertise: procedure must be performed by a trained retinal surgeon under sterile conditions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iluvien may interact with other ocular or systemic agents, requiring careful assessment.

Major Interactions (Avoid): - Other intravitreal corticosteroids: additive risk of IOP elevation and cataract. - Strong CYP3A4 inducers: may reduce local steroid exposure (theoretical). - Ocular anti‑VEGF agents administered within 30 days: may alter pharmacodynamics.

Moderate Interactions (Monitor Closely): - Systemic glucocorticoids: may increase overall steroid load. - Topical ocular NSAIDs: could affect wound healing post‑implant. - Anticoagulants: may increase risk of intraocular hemorrhage during procedure.